Sygnature Discovery Partners with Insmed to develop first-in-class compounds for genetically defined diseases

Sygnature Discovery collaborates with Insmed, bringing together their expertise to develop compounds targeting genetically defined diseases. With seamless teamwork and co-located scientific operations, they aim to create innovative therapeutics for unmet medical needs.

Synthetic chemistry in focus at From Farm to Pharma

We were pleased to host the final ELRIG networking event of 2021 last month at Alderley Park. Synthetic chemistry has...
View Article

Tips for success in candidate profiling – and beyond

Candidate profiling, or late lead optimisation, is the final stage of de-risking and optimising drug candidates with the best chance...
View Article

Formulating for success: A game-changing new facility

This month sees the official opening of our new Form and Formulation department. But why are we bringing formulation scientists...
View Article

Hitting the drug target takes teamwork

Drug discovery programmes can be made or broken by the approaches organisations take in the early stages. As project viability...
View Article